Does Menopause Increase Heart Disease Risk?

Yes, risk generally rises—but menopause is not a single switch from “protected” to “at risk,” and observational evidence cannot assign one person’s risk increase to menopause alone. Humanic Blue’s focus here is the transition and its measurable risk factors, not a one-size-fits-all prediction. An American Heart Association (AHA) scientific statement identifies the transition as a period of unfavorable changes in cholesterol, body composition and measures of blood-vessel health. Age, blood pressure, diabetes, smoking, family and pregnancy history, and physical activity still shape individual risk. Earlier menopause, especially before 45, is also a recognized risk marker in the 2026 US guideline on abnormal blood-fat levels (dyslipidemia).

For readers interested in living longer and better, the AHA frames the transition as an opportunity to review heart and blood-vessel risk before symptoms appear. Blood pressure, cholesterol, blood sugar and personal and reproductive history contribute different information to that assessment. Menopausal hormone therapy can treat symptoms and prevent bone loss in appropriate patients, but the US Preventive Services Task Force (USPSTF) found no net benefit from using systemic hormone therapy (which acts throughout the body) to prevent chronic disease in postmenopausal people without symptoms. That recommendation does not cover treatment of menopause symptoms or premature or surgical menopause.

What changes during the menopause transition?

Menopause is confirmed after 12 months without a menstrual period, but cardiovascular changes do not wait for that date. The American Heart Association’s scientific statement, led by epidemiologist Samar R. El Khoudary, PhD, describes perimenopause—the transition leading up to the final menstrual period—as a time when blood pressure, blood fats, blood-sugar regulation and blood-vessel health can change.

The statement does not say that every woman develops heart disease after menopause. It identifies the transition as a window for prevention because risk factors may become less favorable while routine health care can still change their trajectory.

That distinction matters. Menopause is a life stage; cardiovascular disease is a group of conditions with multiple causes. The National Heart, Lung, and Blood Institute, part of the NIH, lists age, family history, high blood pressure, unhealthy cholesterol, diabetes, smoking and inactivity among the factors that shape heart-disease risk. Menopause belongs in that assessment, but it does not replace it.

Cholesterol shows one of the clearest menopause-linked changes

The Study of Women’s Health Across the Nation, or SWAN, followed a multiethnic group of US women through the menopause transition. In an analysis of about 3,300 participants, epidemiologist Karen A. Matthews, PhD, and colleagues found that total cholesterol, LDL cholesterol and apolipoprotein B rose substantially in the one-year interval before and after the final menstrual period (SWAN analysis). Changes in blood pressure, glucose, insulin and inflammatory markers more closely tracked chronological aging.

That result helps separate two processes that occur at the same time. Some risk factors appear to change specifically around the final menstrual period; others worsen gradually with age. In clinical life, both can matter.

LDL cholesterol measures cholesterol carried in low-density lipoproteins, particles that transport fat in the blood. Apolipoprotein B, or ApoB, reflects the number of particles capable of entering artery walls and contributing to plaque buildup. A later SWAN analysis of about 470 women linked higher LDL cholesterol, ApoB and LDL-particle measures during perimenopause or postmenopause with signs of artery plaque before clinical cardiovascular disease appears, while noting that whether these measures improve prediction of future cardiovascular events still needs study (2023 SWAN analysis).

Body composition can change without telling the whole story on the scale

The AHA statement reports that central or visceral fat tends to increase and lean mass (nonfat tissue) tends to decline during the menopause transition. Visceral fat sits around internal organs and is more metabolically active than fat stored under the skin.

This does not make body weight a diagnosis. The AHA notes that fat around the middle can carry risk even at a body mass index (a weight-for-height measure) in the “normal” range. Waist pattern, blood pressure, lipids, glucose, fitness, smoking and medical history provide information that a scale cannot.

The same statement links the transition with changes in arterial stiffness—how flexible the arteries are—and other measures of blood-vessel health. Many of these data come from observational studies and indirect indicators of disease risk rather than trials showing that one menopause-specific intervention prevents heart attacks. The signal is clinically relevant; the exact causal chain remains incomplete.

Which cardiovascular questions does a weight measurement leave unanswered?

Why is earlier menopause a risk marker?

A pooled analysis led by epidemiologist Dongshan Zhu, PhD, combined individual data from 15 observational studies and about 301,000 women. Compared with menopause at ages 50 to 51, natural menopause before 40 was associated with a 55% higher relative risk of a first nonfatal cardiovascular event, and menopause at ages 40 to 44 with a 30% higher relative risk (Lancet Public Health analysis).

A 55% higher relative risk does not mean 55 extra events per 100 women; the absolute increase depends on how common events were in the comparison group. These group findings do not predict an individual’s probability. The analysis also cannot establish whether earlier menopause caused the added risk. Smoking, genetics, preexisting cardiovascular health and other factors can influence both menopause timing and later disease.

The 2026 ACC/AHA dyslipidemia guideline’s summary for women’s-health clinicians identifies early menopause before 45, preeclampsia (a pregnancy complication involving high blood pressure), gestational diabetes (diabetes during pregnancy) and other reproductive factors as risk markers that can personalize cardiovascular assessment. These markers add context; they do not diagnose cardiovascular disease.

What would distinguish earlier menopause as a marker of risk from a cause of that risk?

Hormone therapy treats symptoms; it is not a heart-health shortcut

The 2022 Menopause Society position statement describes hormone therapy as the most effective treatment for hot flashes and night sweats (vasomotor symptoms), and for menopause-related genital and urinary symptoms. It also says hormone therapy prevents bone loss and fracture. For women younger than 60 or within 10 years of menopause onset who have no medical reason to avoid it, it judged the benefit-risk balance favorable for bothersome symptoms and bone-loss prevention. It also emphasized that risk differs by formulation, dose, duration, route, timing and progestogen use and requires individualization and periodic review.

Those are treatment benefits, not proof that hormone therapy prevents cardiovascular disease or extends life. The USPSTF’s 2022 review found no net benefit from estrogen alone or estrogen plus progestin for primary prevention of chronic conditions in asymptomatic postmenopausal people. Across three trials, neither regimen significantly reduced coronary events; the evidence base was dominated by the Women’s Health Initiative formulations and participants, limiting conclusions about other regimens. The USPSTF explicitly separates prevention from treatment of symptoms and excludes premature or surgical menopause from this recommendation.

This is where two different questions often get merged. “Could hormone therapy be appropriate for my menopause symptoms?” calls for an individualized benefits-and-risks discussion. “Should I take hormones to prevent a heart attack?” is a separate question.

For people covered by the USPSTF recommendation—postmenopausal people without symptoms, excluding premature or surgical menopause—the task force recommends against hormone therapy for primary prevention of chronic disease. That means preventing a first illness, rather than treating an existing symptom or condition.

What belongs in a midlife cardiovascular review?

There is no single laboratory test that converts “menopause” into a cardiovascular-risk score. The AHA and NHLBI instead support assessing established risk factors and the history that gives them context.

Information to review	Why it matters	Important limit
Blood pressure	Hypertension damages arteries and often causes no symptoms	One unusual reading may need confirmation with repeat or home measurements
Lipid panel	LDL cholesterol and triglycerides contribute to risk assessment	Treatment depends on overall risk, not one number in isolation
Blood glucose or A1C (average blood sugar over roughly three months)	Diabetes materially raises cardiovascular risk	The appropriate test and interval depend on health history
Smoking and nicotine exposure	Smoking is a major modifiable cardiovascular risk	Risk falls after quitting but does not disappear immediately
Menopause timing and type	Early or surgical menopause can change risk interpretation	It is a risk marker, not a diagnosis
Pregnancy history	Preeclampsia, gestational diabetes and other complications can signal later risk	These events need to be considered alongside current factors

The current 2026 ACC/AHA dyslipidemia guideline recommends the PREVENT risk calculator to estimate the chance of a first cardiovascular event over 10 or 30 years in adults aged 30 to 79. It then calls for personalizing that estimate with factors not included in the equation and, when useful, selective coronary-calcium testing, a scan that looks for calcium in the heart’s arteries. Early menopause and adverse pregnancy outcomes belong in that discussion; a calculator result is an input, not a final answer.

Symptoms still need ordinary medical attention

Menopause can bring hot flashes, sleep disruption, palpitations and anxiety-like sensations. Those symptoms should not be used to explain away chest pressure, shortness of breath, fainting, sudden weakness or other possible signs of a cardiovascular emergency.

The American Heart Association lists chest discomfort, discomfort in the upper body, shortness of breath, cold sweat, nausea and lightheadedness among heart-attack warning signs and advises calling emergency services. Women can have chest pain, but may also experience less-recognized symptoms. New, severe or rapidly worsening symptoms deserve urgent assessment rather than self-triage as “just hormones.”